Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant human papillomavirus 14-valent vaccine SCT1000

A recombinant, 14-valent, human papillomavirus (HPV) vaccine, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant HPV 14-valent vaccine SCT1000 may generate humoral and cellular immunity against 14 types of HPV antigens, including types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59, thereby preventing infection upon exposure to these 14 types of HPV. In addition, this agent may stimulate cellular immune response against various cancers and genital warts associated with HPV infection.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HPV vaccine SCT1000
human papillomavirus vaccine SCT1000
recombinant HPV 14-valent vaccine SCT1000
Code name:SCT 1000
SCT-1000
SCT1000
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search